Programming from TLM 2022 hosted by AASLD's Special Interest Groups. Programs include:

• ACLF and Clinical Practice
• ALD and NAFLD
• Applications in Public Health
• Cholestatic & Autoimmune and Liver Transplant
• Hepatitis B
• Hepatitis C
• Hepatology Associates
• Hepatotoxicity
• Liver Cancer and Pediatrics
• Liver Fibrosis
• Pediatric Liver Disorders
• Portal Hypertension

A collection of lectures covering the state of the art in liver medicine, originally presented at The Liver Meeting 2022 in Washington, D.C.

Lectures include: 

• Thomas E. Starzl Transplant Surgery State-of-the-Art Lecture, Normothermic Liver Perfusion to Improve Early Allograft Function
• Leon Schiff State-of-the-Art Lecture, The evolution of disease modeling in NAFLD
• Hans Popper State-of-the-Art Lecture, Human Organoids Toward Precision Hepatology
• Hyman J. Zimmerman Hepatotoxicity State-of-the-Art Lecture, Mechanisms of Drug-induced Liver Injury

A series of debriefs covering leading topics from abstracts presented at The Liver Meeting 2022 in Washington, D.C.

Topics include:

• Basic Science
• Hepatitis
• NAFLD
• Portal Hypertension

Explore timely topics in liver disease in a lively debate format as hepatology trainees and practicing hepatologists tackle important, often controversial issues. Debaters will gain skills in critical thinking, balanced argumentation and factual examination of each issues' pros and cons. Debaters, judges and audience members will grapple with opposing scientific, societal, individual and financial viewpoints on current clinical concerns.

DEBATE 1: LIVER TRANSPLANTATION FOR INTRAHEPATIC CHOLANGIOCARCINOMA 
  
University of Michigan 
PRO: Intrahepatic cholangiocarcinoma should be a standard indication for liver transplantation 
Mentor: Robert J Fontana, MD 
Fellows: Jason J Pan, MD and Abhishek Shenoy, MD 
  
Duke University 
CON: Intrahepatic cholangiocarcinoma should be a contraindication to liver transplantation 
Mentor: Lindsay King, MD 
Fellows: Kara Wegermann, MD and Jackie Henson, MD 
  
DEBATE 2: MANDATORY VACCINATION FOR COVID-19 
  
University of Chicago 
PRO: COVID-19 vaccination should be a requirement for liver transplant listing 
Mentor: Anjana Pillai, MD 
Fellows: Anuhya Gampa, MD and Matthew Odenwald, MD 
  
University of Southern California 
CON: COVID-19 vaccination should be recommended but not required for liver transplant listing 
Mentor: Jeffrey Kahn, MD 
Fellows: Sentia Iriana, MD and Jasleen Singh, MD

The hepatology community can contribute to the WHO goals of viral hepatitis elimination. Many countries, including the U.S., appear not to be on track to meet elimination targets by 2030. However, the US and other countries are taking steps to eliminate hepatitis.  Sharing lessons learned, including those resulting from the response to COVID-19, builds capacity for advancing progress toward hepatitis elimination. Understanding the unique successes and challenges in diagnosis, linkage to care and treatment for hepatitis B versus hepatitis C is important.

AASLD President, Raymond Chung, will officially kick off The Liver Meeting® with opening remarks. Immediately following will be the President's Choice Lecture, featuring Dr. John D. Halamka, President of the Mayo Clinic Platform. Dr. Halamka will discuss emerging uses of novel data, AI, and devices that empower AASLD and their stakeholders.

Complex multi-directional interactions occur between the gut microbiota and the liver. A disturbance of this delicate homeostasis can contribute to liver disease. Effects of untargeted microbiota therapies including antibiotics, probiotics and fecal microbiota transplantation, have been assessed in clinical trials.  Precision and targeted modifications such as engineered bacteria, postbiotics and phages, can precisely edit the microbiota and modify liver disease progression.

This program will provide an overview of the growing rates of NASH induced cirrhosis in the East and the West, as well as address guidance on screening for HCC in NASH and treatment.

Single-cell genomics approaches are transforming our understanding of disease pathogenesis, allowing powerful, unbiased exploration of cell states and types at single-cell resolution, resulting in unexpected novel insights into tissue biology and disease mechanisms. In this session, I will describe how we and others have harnessed these approaches to help decode the cellular and molecular mechanisms driving human liver disease.

Don’t overlook any of the research presented at The Liver Meeting® 2021 that directly impacts patients. This year's debrief will briefly review of all the abstracts presented at the meeting that significantly impacted the role of the patient in one condensed session.